Market for drugs from adult stem cells likely to grow, analyst says

06/17/2009 | CNNMoney

The U.S. gross sale of therapies based on adult stem cells is expected to reach more than $100 million this year, and it could climb to $8.2 billion by 2018, a market analyst said. Adult stem cells are more accessible, less expensive to test and less controversial than embryonic stem cells, and they have also been studied for the past 10 to 15 years, making them "ready for prime time," an expert said. Leading companies in the field include Osiris Therapeutics, StemCells, Cytori Therapeutics and Aastrom Biosciences.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA